AstraZeneca PLC Report: Correction Notice on TR-1 Notification Error - August 2025

Here are the key insights extracted from the provided financial report (Form 6-K) for AstraZeneca PLC:

1. Report Date and Context:

• The report is for August 2025, specifically dated 28 August 2025.

2. Company Identification:

• The report pertains to AstraZeneca PLC, a global biopharmaceutical company based in Cambridge, UK, focusing on the development and commercialization of prescription medicines.

3. Notification of Error:

• AstraZeneca was notified by The Capital Group Companies, Inc. that a TR-1 notification they submitted on 25 August 2025 was provided in error. This notification had been announced by AstraZeneca on 26 August 2025.

4. Correction to Shareholders:

• Shareholders are advised to disregard the erroneous TR-1 notification from 26 August and refer instead to a previous TR-1 notification related to Capital Group announced on 21 August 2025.

5. Accessing Correct Information:

• The correct TR-1 notification can be accessed via a provided link to the regulatory story on AstraZeneca's investor relations website.

6. Company Operations:

• AstraZeneca specializes in several therapeutic areas, including Oncology, Rare Diseases, and various Biopharmaceuticals, and markets its innovative medicines in over 125 countries.

7. Contact Information:

• The report includes contact details for the Investor Relations Team and mentions the Company Secretary, Matthew Bowden.

8. Regulatory Compliance:

• The filing is made under the Securities Exchange Act of 1934, complying with Form 6-K requirements.

Overall, this section primarily serves as a correction notice regarding a notification error related to shareholder holdings, while also providing essential company information and regulatory disclosures.